Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies

References

• Hudis CA. Current status and future directions in breast cancer therapy. Clin Breast Cancer 2003; 4:Suppl 2 S70 - 5; http://dx.doi.org/10.3816/CBC.2003.s.018; PMID: 14667277
   PubMedGoogle Scholar
• Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34:791 - 808; http://dx.doi.org/10.1016/S0959-8049(97)10157-5; PMID: 9797688
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177 - 82; http://dx.doi.org/10.1126/science.3798106; PMID: 3798106
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 2001; 7:171 - 7; http://dx.doi.org/10.1007/BF03032345; PMID: 11692142
   PubMedGoogle Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37:Suppl 4 S3 - 8; http://dx.doi.org/10.1016/S0959-8049(01)00230-1; PMID: 11597398
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7:505 - 16; http://dx.doi.org/10.1038/nrm1962; PMID: 16829981
   PubMed Web of Science ®Google Scholar
• Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 2006; 16:649 - 56; http://dx.doi.org/10.1016/j.tcb.2006.10.008; PMID: 17085050
   PubMed Web of Science ®Google Scholar
• Ranson M, Sliwkowski MX. Perspectives on anti-HER monoclonal antibodies. Oncology 2002; 63:Suppl 1 17 - 24; http://dx.doi.org/10.1159/000066203; PMID: 12422051
   PubMed Web of Science ®Google Scholar
• Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP. Development of Herceptin resistance in breast cancer cells. Cytometry A 2004; 57:86 - 93; http://dx.doi.org/10.1002/cyto.a.10095; PMID: 14750129
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317 - 28; http://dx.doi.org/10.1016/S1535-6108(04)00083-2; PMID: 15093539
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127 - 37; http://dx.doi.org/10.1016/S1535-6108(02)00097-1; PMID: 12204533
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756 - 60; http://dx.doi.org/10.1038/nature01392; PMID: 12610629
   PubMed Web of Science ®Google Scholar
• Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429 - 40; http://dx.doi.org/10.1016/j.ccr.2009.03.020; PMID: 19411071
   PubMed Web of Science ®Google Scholar
• de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends J-W, Hoogenboom HR. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274:18218 - 30; http://dx.doi.org/10.1074/jbc.274.26.18218; PMID: 10373423
   PubMed Web of Science ®Google Scholar
• Wang YX, Jia PY, Wang YX, Qiao YY, Yang RF, Zhou LJ. [Cloning of human scFv against soman transition state analogues (P6) from a large phage antibody library]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010; 26:250 - 2; PMID: 20230690
   PubMedGoogle Scholar
• Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem 2013; 288:27059 - 67; http://dx.doi.org/10.1074/jbc.M113.491530; PMID: 23943614
   PubMed Web of Science ®Google Scholar
• Fisher RD, Ultsch M, Lingel A, Schaefer G, Shao L, Birtalan S, Sidhu SS, Eigenbrot C. Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine. J Mol Biol 2010; 402:217 - 29; http://dx.doi.org/10.1016/j.jmb.2010.07.027; PMID: 20654626
   PubMed Web of Science ®Google Scholar
• Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem 2013; 288:27059 - 67; http://dx.doi.org/10.1074/jbc.M113.491530; PMID: 23943614
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132 - 9; http://dx.doi.org/10.1200/JCO.2010.29.7101; PMID: 21060033
   PubMed Web of Science ®Google Scholar
• Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12:541 - 52; http://dx.doi.org/10.1016/S1097-2765(03)00350-2; PMID: 14527402
   PubMed Web of Science ®Google Scholar
• Alvarado D, Klein DE, Lemmon MA. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell 2010; 142:568 - 79; http://dx.doi.org/10.1016/j.cell.2010.07.015; PMID: 20723758
   PubMed Web of Science ®Google Scholar
• Alvarado D, Klein DE, Lemmon MA. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature 2009; 461:287 - 91; http://dx.doi.org/10.1038/nature08297; PMID: 19718021
   PubMed Web of Science ®Google Scholar
• Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927 - 48; http://dx.doi.org/10.1006/jmbi.1997.1354; PMID: 9367782
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463 - 75; http://dx.doi.org/10.1038/nrc2656; PMID: 19536107
   PubMed Web of Science ®Google Scholar
• Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19:124 - 34; http://dx.doi.org/10.1016/j.ceb.2007.02.008; PMID: 17314037
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127 - 37; http://dx.doi.org/10.1038/35052073; PMID: 11252954
   PubMed Web of Science ®Google Scholar
• Silva F, Cisternas M, Specks U. TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis. Curr Rheumatol Rep 2012; 14:501 - 8; http://dx.doi.org/10.1007/s11926-012-0290-2; PMID: 22956157
   PubMedGoogle Scholar
• Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11:495 - 505; http://dx.doi.org/10.1016/S1097-2765(03)00048-0; PMID: 12620236
   PubMed Web of Science ®Google Scholar
• Horan T, Wen J, Arakawa T, Liu N, Brankow D, Hu S, Ratzkin B, Philo JS. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. J Biol Chem 1995; 270:24604 - 8; http://dx.doi.org/10.1074/jbc.270.41.24604; PMID: 7592681
   PubMed Web of Science ®Google Scholar
• Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988; 8:5570 - 4; PMID: 2907606
   PubMed Web of Science ®Google Scholar
• Chantry A. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors. J Biol Chem 1995; 270:3068 - 73; PMID: 7531698
   PubMed Web of Science ®Google Scholar
• Penuel E, Akita RW, Sliwkowski MX. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem 2002; 277:28468 - 73; http://dx.doi.org/10.1074/jbc.M202510200; PMID: 12000754
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13:1323 - 32; http://dx.doi.org/10.1002/ibd.20225; PMID: 17636564
   PubMed Web of Science ®Google Scholar
• Miura GI, Buglino J, Alvarado D, Lemmon MA, Resh MD, Treisman JE. Palmitoylation of the EGFR ligand Spitz by Rasp increases Spitz activity by restricting its diffusion. Dev Cell 2006; 10:167 - 76; http://dx.doi.org/10.1016/j.devcel.2005.11.017; PMID: 16459296
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX. Pari passu dimers of dimers. Proc Natl Acad Sci U S A 2012; 109:13140 - 1; http://dx.doi.org/10.1073/pnas.1209959109; PMID: 22851769
   PubMed Web of Science ®Google Scholar
• Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res 2008; 68:2400 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-07-6663; PMID: 18381448
   PubMed Web of Science ®Google Scholar
• Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14:309 - 14; http://dx.doi.org/10.1038/nbt0396-309; PMID: 9630891
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 1992; 226:889 - 96; http://dx.doi.org/10.1016/0022-2836(92)90639-2; PMID: 1507232
   PubMed Web of Science ®Google Scholar
• He M, Menges M, Groves MA, Corps E, Liu H, Brüggemann M, Taussig MJ. Selection of a human anti-progesterone antibody fragment from a transgenic mouse library by ARM ribosome display. J Immunol Methods 1999; 231:105 - 17; http://dx.doi.org/10.1016/S0022-1759(99)00144-1; PMID: 10648931
   PubMed Web of Science ®Google Scholar
• Hudziak RM, Ullrich A. Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum. J Biol Chem 1991; 266:24109 - 15; PMID: 1684181
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285 - 9; http://dx.doi.org/10.1073/pnas.89.10.4285; PMID: 1350088
   PubMed Web of Science ®Google Scholar
• Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter Jr. CW, Sweet RM, eds. Macromolecular Crystallography, part A: Academic Press, 1997:307-26.
   Google Scholar
• McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 2005; 61:458 - 64; http://dx.doi.org/10.1107/S0907444905001617; PMID: 15805601
   PubMed Web of Science ®Google Scholar
• Matthews BW. Solvent content of protein crystals. J Mol Biol 1968; 33:491 - 7; http://dx.doi.org/10.1016/0022-2836(68)90205-2; PMID: 5700707
   PubMed Web of Science ®Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126 - 32; http://dx.doi.org/10.1107/S0907444904019158; PMID: 15572765
   PubMed Web of Science ®Google Scholar
• Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 2002; 58:1948 - 54; http://dx.doi.org/10.1107/S0907444902016657; PMID: 12393927
   PubMed Web of Science ®Google Scholar
• Laskowski R, MacArthur M, Moss D, Thornton J. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26:283 - 91; http://dx.doi.org/10.1107/S0021889892009944
   Web of Science ®Google Scholar
• DeLano W. The PyMOL Molecular Graphics System 2002
   Google Scholar
• Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 1999; 19:6845 - 57; PMID: 10490623
   PubMed Web of Science ®Google Scholar
• Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003; 171:1918 - 26; PMID: 12902494
   PubMed Web of Science ®Google Scholar